{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T21:58:04Z","timestamp":1783461484964,"version":"3.55.0"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Liquid biopsy for detection of circulating tumor DNA (ctDNA) offers a promising, non-invasive strategy for real-time monitoring of cancer. We aimed to develop a universal and sensitive one-tube droplet digital PCR (ddPCR) multiplex assay able to detect ctDNA in plasma from metastatic prostate cancer (PCa) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Publicly available array data are applied to identify methylation signatures specific to both normal and cancerous prostate tissue. The assay is based on the highly sensitive ddPCR technology, and tissue and plasma samples are analyzed using the QX600 ddPCR multiplexing platform from BioRad.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified three novel genomic regions,\n                      <jats:italic>ACTRT2<\/jats:italic>\n                      ,\n                      <jats:italic>EVX1,<\/jats:italic>\n                      and\n                      <jats:italic>HOXD13<\/jats:italic>\n                      , containing CpG-methylation signatures specific to normal and cancerous prostate tissue. We successfully targeted the three biomarkers in a single-tube methylation-specific multiplex ddPCR (mm-ddPCR) assay along with two previously reported PCa-specific hypermethylated CpG biomarkers,\n                      <jats:italic>DOCK2<\/jats:italic>\n                      and\n                      <jats:italic>HAPLN3<\/jats:italic>\n                      , and the\n                      <jats:italic>ALB<\/jats:italic>\n                      reference gene. The mm-ddPCR assay consistently detected\n                      <jats:italic>ACTRT2<\/jats:italic>\n                      ,\n                      <jats:italic>EVX1,<\/jats:italic>\n                      and\n                      <jats:italic>HOXD13<\/jats:italic>\n                      across all samples originating from prostate-derived tissue. In contrast, the\n                      <jats:italic>HAPLN3<\/jats:italic>\n                      and\n                      <jats:italic>DOCK2<\/jats:italic>\n                      biomarkers were predominantly detected in PCa tissue. We also demonstrate that the five ctDNA biomarkers can be detected in plasma samples from metastatic castration-resistant PCa (mCRPC) patients with a 95% CI (85%, 100%) using the mm-ddPCR assay.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This work demonstrates that the mm-ddPCR assay offers a simple, fast, cost-effective, sensitive, and universal tool for the detection of ctDNA biomarkers in plasma from mCRPC patients. Further studies are required to explore its potential for PCa risk stratification and treatment guidance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0340786","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T18:21:41Z","timestamp":1769710901000},"page":"e0340786","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Methylation-specific, universal, and highly sensitive identification of ctDNA in prostate cancer by multiplex droplet digital PCR"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9330-8734","authenticated-orcid":true,"given":"S\u00f8ren","family":"Kahns","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed H.","family":"Zedan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads M.","family":"Aagaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa M. D.","family":"Canto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne","family":"Kj\u00e6r-Frifeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stine V.","family":"Eriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine V.","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6668-4714","authenticated-orcid":true,"given":"Jonna S.","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palle J. S.","family":"Osther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben F.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke F.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"issue":"25","key":"pone.0340786.ref001","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMsb2000250","article-title":"Reconsidering the trade-offs of prostate cancer screening","volume":"382","author":"JE Shoag","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"pone.0340786.ref002","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMms1914228","article-title":"Reconsidering prostate cancer mortality - the future of PSA screening","volume":"382","author":"HG Welch","year":"2020","journal-title":"N Engl J Med"},{"issue":"10437","key":"pone.0340786.ref003","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"ND James","year":"2024","journal-title":"Lancet"},{"key":"pone.0340786.ref004","article-title":"Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis","volume":"362","author":"D Ilic","year":"2018","journal-title":"BMJ"},{"issue":"3","key":"pone.0340786.ref005","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.urolonc.2013.09.017","article-title":"Prostate cancer biomarkers: an update","volume":"32","author":"J Romero Otero","year":"2014","journal-title":"Urol Oncol"},{"issue":"1","key":"pone.0340786.ref006","first-page":"99","article-title":"Prostate-specific antigen and other serum and urine markers in prostate cancer","volume":"1846","author":"C Stephan","year":"2014","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"pone.0340786.ref007","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41416-020-01047-5","article-title":"Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond","volume":"124","author":"L Keller","year":"2021","journal-title":"Br J Cancer"},{"issue":"8","key":"pone.0340786.ref008","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1080\/15384047.2019.1598759","article-title":"Life and death of circulating cell-free DNA","volume":"20","author":"A Kustanovich","year":"2019","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"pone.0340786.ref009","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.annonc.2019.11.014","article-title":"Circulating breast-derived DNA allows universal detection and monitoring of localized breast cancer","volume":"31","author":"J Moss","year":"2020","journal-title":"Ann Oncol"},{"issue":"6","key":"pone.0340786.ref010","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","article-title":"Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA","volume":"31","author":"CCGA Consortium","year":"2020","journal-title":"Ann Oncol"},{"issue":"6","key":"pone.0340786.ref011","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3390\/cells9061362","article-title":"Epigenetic analysis of circulating tumor DNA in localized and metastatic prostate cancer: evaluation of clinical biomarker potential","volume":"9","author":"MT Bjerre","year":"2020","journal-title":"Cells"},{"issue":"1","key":"pone.0340786.ref012","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.annonc.2022.09.163","article-title":"Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study","volume":"34","author":"ZR Reichert","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"pone.0340786.ref013","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/s41467-024-45475-w","article-title":"Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer","volume":"15","author":"NM Fonseca","year":"2024","journal-title":"Nat Commun"},{"issue":"4","key":"pone.0340786.ref014","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/clinchem\/hvac224","article-title":"Prognostic value of low-pass whole genome sequencing of circulating tumor DNA in metastatic castration-resistant prostate cancer","volume":"69","author":"M N\u00f8rgaard","year":"2023","journal-title":"Clin Chem"},{"issue":"15","key":"pone.0340786.ref015","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1158\/1078-0432.CCR-22-2998","article-title":"Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer","volume":"29","author":"SH Tolmeijer","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"18","key":"pone.0340786.ref016","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1158\/1078-0432.CCR-24-1096","article-title":"Circulating tumor DNA assessment for treatment monitoring adds value to PSA in metastatic castration-resistant prostate cancer","volume":"30","author":"CJ Sweeney","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"16","key":"pone.0340786.ref017","article-title":"Liquid biopsy in the clinical management of cancers","volume":"25","author":"HY Ho","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"1","key":"pone.0340786.ref018","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/14737159.2018.1400384","article-title":"Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective","volume":"18","author":"M Postel","year":"2018","journal-title":"Expert Rev Mol Diagn"},{"issue":"5","key":"pone.0340786.ref019","doi-asserted-by":"crossref","first-page":"2103056","DOI":"10.1183\/13993003.03056-2021","article-title":"Universal lung epithelium DNA methylation markers for detection of lung damage in liquid biopsies","volume":"60","author":"J Magenheim","year":"2022","journal-title":"Eur Respir J"},{"issue":"11","key":"pone.0340786.ref020","article-title":"Circulating tumor DNA methylation detection as biomarker and its application in tumor liquid biopsy: advances and challenges","volume":"5","author":"L Li","year":"2024","journal-title":"MedComm (2020)"},{"issue":"1","key":"pone.0340786.ref021","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1038\/s41467-018-07466-6","article-title":"Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease","volume":"9","author":"J Moss","year":"2018","journal-title":"Nat Commun"},{"issue":"12","key":"pone.0340786.ref022","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1158\/2159-8290.CD-21-0634","article-title":"Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease","volume":"11","author":"EJ Moding","year":"2021","journal-title":"Cancer Discov"},{"issue":"12","key":"pone.0340786.ref023","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMp1607591","article-title":"Toward a shared vision for cancer genomic data","volume":"375","author":"RL Grossman","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0340786.ref024","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/nar\/30.1.207","article-title":"Gene expression omnibus: NCBI gene expression and hybridization array data repository","volume":"30","author":"R Edgar","year":"2002","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"pone.0340786.ref025","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/bioinformatics\/btu049","article-title":"Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays","volume":"30","author":"MJ Aryee","year":"2014","journal-title":"Bioinformatics"},{"key":"pone.0340786.ref026","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.cca.2015.04.015","article-title":"Controls to validate plasma samples for cell free DNA quantification","volume":"446","author":"N Pallisgaard","year":"2015","journal-title":"Clin Chim Acta"},{"issue":"10","key":"pone.0340786.ref027","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.3390\/cancers13102451","article-title":"The clinical value of measuring circulating HPV DNA during chemo-radiotherapy in squamous cell carcinoma of the anus","volume":"13","author":"AC Lef\u00e8vre","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"pone.0340786.ref028","article-title":"BiSearch: primer-design and search tool for PCR on bisulfite-treated genomes","volume":"33","author":"GE Tusn\u00e1dy","year":"2005","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"pone.0340786.ref029","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1373\/clinchem.2015.253609","article-title":"A study of hypermethylated circulating tumor DNA as a universal colorectal cancer biomarker","volume":"62","author":"S Garrigou","year":"2016","journal-title":"Clin Chem"},{"key":"pone.0340786.ref030","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-1-4939-7778-9_3","article-title":"Fundamentals of Counting Statistics in Digital PCR: I Just Measured Two Target Copies-What Does It Mean?","volume":"1768","author":"S Tzonev","year":"2018","journal-title":"Methods Mol Biol"},{"issue":"1","key":"pone.0340786.ref031","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12943-021-01445-0","article-title":"Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies","volume":"21","author":"T Dillinger","year":"2022","journal-title":"Mol Cancer"},{"issue":"1","key":"pone.0340786.ref032","doi-asserted-by":"crossref","first-page":"6467","DOI":"10.1038\/s41467-022-34012-2","article-title":"The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors","volume":"13","author":"S Chen","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"pone.0340786.ref033","doi-asserted-by":"crossref","DOI":"10.1002\/ctd2.279","article-title":"Role of DNA methylation in cancer development and its clinical applications","volume":"4","author":"S Sonar","year":"2024","journal-title":"Clinical and Translational Dis"},{"issue":"1","key":"pone.0340786.ref034","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/JU.0000000000002758","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, Part II: principles of active surveillance, principles of surgery, and follow-up","volume":"208","author":"JA Eastham","year":"2022","journal-title":"J Urol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0340786","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T18:21:46Z","timestamp":1769710906000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0340786"}},"subtitle":[],"editor":[{"given":"Mohamed","family":"Gouda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0340786","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]}}}